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N‐methyl‐D‐aspartate receptors (NMDARs) are a family of ionotropic
glutamate receptors mainly known to mediate excitatory synaptic
transmission and plasticity. Interestingly, low‐dose NMDAR anta‐
gonists lead to increased, instead of decreased, functional connectivity;
and they could cause schizophrenia‐ and/or antidepressant‐like
behavior in both humans and rodents. In addition, human genetic
evidences indicate that NMDAR loss of function mutations underlie
certain forms of epilepsy, a disease featured with abnormal brain
hyperactivity. Together, they all suggest that under certain conditions,
NMDAR activation actually lead to inhibition, but not excitation,
of the global neuronal network. Apparently, these phenomena are
rather counterintuitive to the receptor’s basic role in mediating
excitatory synaptic transmission. How could it happen? Recently,
this has become a crucial question in order to fully understand the
complexity of NMDAR function, particularly in disease. Over the
past decades, different theories have been proposed to address this
question. These include theories of “NMDARs on inhibitory neurons
are more sensitive to antagonism”, or “basal NMDAR activity
actually inhibits excitatory synapse”, etc. Our review summarizes
these efforts, and also provides an introduction of NMDARs,
inhibitory neurons, and their relationships with the related diseases.
Advances in the development of novel NMDAR pharmacological
tools, particularly positive allosteric modulators, are also included to
provide insights into potential intervention strategies.
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1

Introduction

Glutamate is the major excitatory neurotrans‐
mitter in the mammalian central nervous system.
It acts via activating two types of receptors:

metabotropic glutamate receptor (mGluR) and
ionotropic glutamate receptor (iGluR). iGluRs
include three types: a‐amino‐3‐hydroxy‐5‐methyl‐
4‐isoxazolepropionate receptors (AMPARs), N‐
methyl‐D‐aspartate receptors (NMDARs) and
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Kainate receptors (KARs) [1]. NMDARs are
glutamate‐gated cation channels permeable to
sodium, calcium, and potassium. Importantly,
the calcium influx through NMDARs serves as
a trigger for several types of synaptic plasticity
and is critical for many other NMDAR‐evoked
physiological and pathological signaling events
[2]. NMDAR dysfunction contributes to various
brain disorders, such as schizophrenia, depression
and epilepsy, etc. [3]. However, the precise role
of NMDARs in these diseases remains elusive.
1.1

NMDARs subunit composition and
distribution

In the 1980s, based on patch‐clamp studies of
neuronal activity it was first proposed that
NMDARs were composed of different subtypes
[1, 3, 4]. Subsequent cloning and expression studies
revealed that there are seven different subtypes,
including GluN1, four GluN2 (A‐D), and two
GluN3 (A and B). NMDARs are heterotetramers
assembled from two obligatory GluN1 subunits
plus two GluN2 or GluN3 subunits. NMDARs
containing GluN3 form either di‐heteromeric
(GluN1/GluN3) or tri‐heteromeric (GluN1/GluN2/
GluN3) complexes [1]. Among these subunits,
GluN1 is encoded by one single gene with 8
different isoforms (GluN1‐1a/2a/3a/4a and GluN1‐
1b/2b/3b/4b) produced by alternative mRNA
splicing. The “b” isoforms possess an additional
extracellular 21‐amino‐acid stretch encoded by
exon 5. This additional fragment significantly
affects gating and pharmacological properties
of NMDARs [5]. GluN1 shows about 25%–28%
homology to other iGluR subunits [6]. The four
GluN2 subunits are encoded by four different
genes sharing 18%–20% homology to GluN1 [7].
GluN3A and 3B are also encoded by two different
genes. GluN3A shows a higher homology (57%)
to GluN3B and a lower homology to GluN1 (27%)
and GluN2 (24%–29%) [8]. GluN3B is only 17%–
21% homologous to GluN1 and GluN2 [9].

Ligand‐binding studies have revealed that
NMDARs are distributed throughout the brain
with a higher expression level in the forebrain.
The distribution patterns of NMDAR subunits
in brain have been described with molecular
techniques [4, 10, 11]. Specifically, in adult rodents,
GluN1 mRNA is expressed ubiquitously throug‐
hout the brain. Among eight GluN1 splice variants,
GluN1‐1(a and b) and GluN1‐4 (a and b) show
a complementary expression pattern, with the
former being concentrated in the hippocampus
and cortex whereas the latter primarily in caudal
regions such as the thalamus and cerebellum.
Notably, the regions expressing GluN1‐a and
GluN1‐b variants are largely overlapping; how‐
ever, their relative abundances vary across different
regions. For instance, the GluN1‐a isoform is
expressed in all pyramidal neurons in hippo‐
campus, whereas GluN1‐b is mainly located in
the CA3 region of hippocampus [4, 12].
Rodent data indicate that distributions of GluN2
subunits vary across different regions of the
brain. GluN2A exhibits a widespread distribution
throughout the adult brain, especially in the cortex,
hippocampus, and cerebellum [13]. In contrast,
the expression of GluN2B is relatively restricted
in the forebrain and mostly distributed in cerebral
cortex, hippocampus, olfactory bulb, and caudate
putamen. GluN2C is largely restricted to cere‐
bellum and olfactory bulb. GluN2D is weakly
expressed and mostly distributed within the
diencephalon and mesencephalon.
GluN3A and GluN3B are the two isoforms of
the GluN3 subunit, exhibiting restricted spatio‐
temporal distributions. Previously, it was recog‐
nized that GluN3A is more widely expressed than
GluN3B [9]. GluN3A exhibits high abundancy
in olfactory bulb, cerebellum, CA1 region of the
hippocampus, hypothalamus, nuclei of amygdala
and certain parts of cortex [14, 15], while GluN3B
expression is restricted to hippocampus, spinal
cord, brain stem and cerebellum [16, 17]. GluN3B
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was also found to be expressed in the forebrain,
including cerebral cortex, hippocampus, caudo‐
putamen, and nucleus accumbens. [8, 18].

2

Switching of NMDAR expression pattern
during development

The NMDAR subunits undergo changes in their
expression patterns during development. Although
GluN1 subunit is ubiquitously expressed since
the early embryonic stage, its expression level
varies. In situ hybridization experiments demon‐
strate that GluN1 expression starts at embryonic
stage 14 (E14), rises to peak around the third
postnatal week [19‐21], and then decreases to a
relatively stable level. All GluN1 isoforms follow
the similar expression profile during development
[22].
The GluN2 subunits impact functional hetero‐
geneity of NMDARs, and show prominently
different spatiotemporal expression profiles [13].
In the embryonic rodent brain, only GluN2B
and GluN2D are expressed. Their expression
starts as early as E14 and gradually increases
with development. GluN2B expression reaches a
relatively high level after birth and continues to
increase until it peaks around P7‐10. Within the
first postnatal week, GluN2B becomes widely
distributed in the brain, but after P7‐10, its
expression is restricted to forebrain, including
cortex, hippocampus, striatum, and olfactory bulb.
GluN2D, in contrast to the widely‐distributed
and highly‐expressed GluN2B, exhibits a striking
decrease in the expression after birth and in the
adulthood. It only expresses at low levels in
diencephalon and brainstem [4]. Both GluN2A
and GluN2C start to express in hippocampus
and cerebellum after birth. Whereas the expression
of the GluN2A increases sharply during the first
two postnatal weeks and gradually spreads out
to the whole CNS in adulthood, the expression
of GluN2C is mainly confined to cerebellum and
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olfactory bulb.
Among the four GluN2 subunits, GluN2A and
GluN2B are the predominant subunits found in
the cortex and the hippocampus. During the
early developmental stages, GluN2B‐containing
NMDARs are the primary types at synapses. After
birth, during the second postnatal week, the
GluN2A subunits start to express and gradually
replace GluN2B from the synapses [2, 4].
The GluN3A and GluN3B subunits also have
distinct expression patterns. GluN3A starts
expressing at around E15 within the spinal
cord, tegmentum, hypothalamus, and thalamus.
Its expression gradually increases and peaks at
around P8, then rapidly declines to the adult
level by P20 [14, 23]. GluN3B expression begins
during early postnatal stages, peaks at around P14,
and then stays plateaus throughout adulthood.
GluN3B distribution was initially thought to be
confined to brainstem and spinal cord, but it
has been lately discovered to be ubiquitously
distributed [14, 15, 18].

3

GABAergic inhibitory interneurons

Neuronal microcircuits are composed of both
excitatory and inhibitory neurons. The fine
balance of excitation and inhibition is critical
for many brain functions. The vast majority of
neurons in the cerebral cortex (about 80%) are
excitatory glutamatergic neurons, also called prin‐
cipal neurons. These neurons have long axons
and can project across different brain regions.
Inhibitory neurons account for about 20% of cor‐
tical neurons. Compared with principal neurons,
inhibitory neurons generally have smaller soma,
shorter axons, and project locally; therefore, they
are also called interneurons. Interneurons are
GABAergic, releasing inhibitory neurotransmitter
γ‐aminobutyric acid (GABA). GABA acts on
GABA‐A type ionotropic receptors to mediate fast
synaptic inhibition, generating hyperpolarization
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and, therefore, inhibition in the brain. It is the
main source of inhibition in the mammalian brain.
3.1

Origin and classification of interneuron

Glutamatergic neurons are originated from the
ventricular and sub‐ventricular areas of the em‐
bryonic brain, while cortical GABAergic neurons
are generated in medial ganglionic eminences
(MGE) and caudal ganglionic eminences (CGE)
in ventral telencephalon [24, 25]. Around E13.5,
GABAergic neurons migrate tangentially to pro‐
per cortical regions crossing sub‐ventricular zone
(SVZ) and marginal zone (MZ), and then radially
to the cortical plate (CP) [26, 27].
Cortical GABAergic inhibitory neurons exhibit
tremendous diversity in morphology, electro‐
physiological properties, molecular expression
profiles, and input and output connectivity [28–30].
Therefore, different criteria has been proposed to
classify interneurons [31]. The most widely used
classification is based on the expression of specific
molecular markers, by which interneurons can be
divided into three major types: calcium‐binding
protein parvalbumin (PV), neuropeptide somato‐
statin (Sst), or ionotropic serotonin receptor
5HT3a (5HT3aR) positive interneurons [32, 33]. PV
interneurons are the most populous GABAergic
interneurons in neocortex, accounting for ~40%.
Sst and 5HT3aR interneurons each account for
~30% [33].
3.2

Interneuron function

GABAergic interneurons mainly provide inhi‐
bitory input to reduce excitability of principal
neurons, which is critical for the maintenance of
excitation‐inhibition balance [34]. They could also
inhibit other interneurons to cause disinhibition
[35, 36]. For example, a subtype of vasoactive‐
intestinal peptide (VIP) interneurons mediates
disinhibitory control in mouse auditory cortex
(ACx) and medial prefrontal cortex (mPFC) by
transiently inhibiting Sst and PV interneurons [37].

Interneurons also contribute to synchronized
oscillations [38]. Neural oscillations are rhythmic
or repetitive patterns of neural activity in the
central nervous system, and are thought to play
an important role in processing of neural infor‐
mation, such as perception, motor control and
memory [39]. It has been well‐established that
interneurons are involved in generation and
propagation of cortical oscillations [40]. The hy‐
pothesis that excitatory‐inhibitory feedback loop
was first proposed to explain the contribution of
interneurons to spike timing during fast oscillations
[41, 42], which indicates synchronizing may be
partially dependent on the ability of GABAergic
interneurons to entrain the firing of principal
neurons [43]. Inhibitory loop was later proposed
[42]. Interneurons innervate not only the prin‐
cipal neurons, but also themselves and other
interneurons. Such interneurons self‐innervation
can increase the precision and regulate oscillations
generation [44]. The propagation of hippo‐
campal oscillation is found to be dependent on
excitatory connection onto interneurons, rather
than excitatory‐excitatory connection [45, 46].
Gamma oscillations, a kind of oscillations in
the brain, are thought to underlie cognitive and
motor functions [45, 47]. Mounting evidence
supports that gamma oscillations critically relies
on entrainment by a phasic inhibitory drive [48,
49], and fast‐spiking interneurons expressing PV
are critical to gamma oscillations [41, 44, 50]. For
example, in knock‐out (KO) animals of calcium‐
binding protein parvalbumin (PV), the power of
kainate‐induced gamma oscillations is appro‐
ximately twice as much as that in wild‐type (WT),
suggesting that PV interneuron contributes to
gamma oscillations [32].
Interneuronal dysfunctions have been impli‐
cated in a number of brain diseases. Schizophrenia
is a severe psychiatric disorder, and traditionally
thought to be caused by hyperfunction of
dopaminergic neurotransmission, which cannot
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explain the negative symptoms and cognitive
deficits of schizophrenia [51]. Pharmacological
and genetic evidences suggest that disrupted
glutamatergic function may underlie schizophrenia
[52–55]. And it was proposed that dysfunction
of PV interneurons in cerebral cortex results in
glutamatergic deficits as seen in schizophrenia
[56–58]. Expression of interneurons marker pro‐
teins PV and glutamate decarboxylase 67 kDa
(GAD 67) are decreased in the brain of schizo‐
phrenia patients [59, 60]. Bipolar disorder (BPD)
is a mental disorder and is one of the leading
cause of disability [61]. Postmortem studies
have reported that the density of hippocampal
interneurons is decreased in bipolar disorder
patients [61, 62]. Reduced expression of Sst and
VIP is also seen in dorsolateral prefrontal cortex
[63]. Epilepsy is a group of neurological disor‐
ders and thought to be due to the unbalanced
excitation‐inhibition in the brain. GABAA receptors
play critical roles in inhibitory neurotransmission.
Clinical and experimental evidences suggest that
perturbation of GABAA signaling contributes to
epilepsy [64]. In addition, many GABAA receptor
mutations are known to cause early‐life epilepsy,
including loss of function mutations or deletions
of GABAA receptor subunit genes [65, 66].
Dysfunction of interneurons is also related to
autism spectrum disorders (ASDs). ASDs are
neurodevelopmental syndromes characterized
by cognitive deficits, impaired language skill
and social behavior [34]. Genetic evidence also
links ASDs to genes encoding the β3, α5 and γ3
subunits of GABAA receptors [67, 68]. Cortical PV
interneurons [69] and GAD67 are both decreased
in ASDs [70, 71].

4

Why NMDAR blockade causes excitation
instead of inhibition?

excitatory synaptic transmission. It is intuitive
to predict that NMDAR blockade should inhibit
neural circuit activity in the brain. Following this
prediction, NMDAR antagonists, phencyclidine
and ketamine, have been successfully utilized as
anesthetics [72].
Interestingly, however, low doses of NMDAR
inhibitors actually cause excitation instead of
inhibition in the brain [73]. These observations
contradict to the conventional knowledge about
NMDAR function. Why does inhibition of an
excitatory neurotransmitter receptor cause excita‐
tion instead of inhibition? The phenomenon has
triggered profound interests ever since it was
discovered, as the underlying mechanism might
be critical in understanding the role of NMDARs
in various brain disorders. Over the past decades,
different mechanisms have been proposed to
explain this paradox. For example, since both
excitatory and inhibitory neurons receive excita‐
tory inputs and have NMDARs at those synapses,
one possibility is that NMDAR inhibitors at low
doses preferentially act on interneurons in vivo
[74], therefore they decrease interneuron activity
and result in disinhibition of the neuronal net‐
work. An alternative explanation is that basal
NMDAR activity suppresses neuronal activity in
excitatory neurons; and when NMDAR inhibitors
are applied, they alleviate this inhibition, therefore.
causing disinhibition [75]. There are also other
ways that NMDARs could impact inhibitory
circuits. For example, recent studies have revealed
that NMDARs on excitatory neurons are critical
for the development of inhibitory synapses [76],
and NMDARs at GABAergic synapses could
impact GABAergic transmission [77, 78]. In
addition, NMDARs are critical for the plasticity of
GABAergic synapses onto excitatory neurons [79].
Each of these proposed mechanisms is discussed

NMDARs are glutamate receptors mediating
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NMDARs promote GABAergic synapse
function and development in excitatory
neurons to boost inhibition

Glutamate is the major excitatory neurotran‐
smitter in mammalian central nervous system.
During the fast synaptic transmission, glutamate
activates AMPARs and NMDARs at the post‐
synaptic membrane. NMDARs are traditionally
regarded as postsynaptic receptors; however,
both anatomical and physiological evidences sug‐
gest existence of presynaptic NMDARs [80, 81].
While postsynaptic NMDARs mediate glutama‐
tergic excitatory neurotransmission, presynaptic
NMDARs modulate transmitter release in many
brain regions, including cerebellum, entorhinal
cortex, neocortex, and spinal cord [3], although
the precise function of presynaptic NMDARs in
excitatory synapses remains unclear. Interestingly,
presynaptic NMDARs also exist at GABAergic
presynaptic terminals in cerebellum and neocor‐
tex [77]. These presynaptic NMDARs modulate
GABAergic synapses by increasing the size of
GABAergic synaptic terminals and spontaneous
GABA release [82] (Fig. 1, Mechanism B). Presy‐
naptic NMDARs also facilitate GABAergic
synaptic transmission in immature neocortex
in a developmentally regulated manner, which
involves GluN2B‐containing NMDARs and
impacts neocortical circuit development [78].
Activation of presynaptic NMDARs increases
GABA release leading to an enhanced frequency
of miniature inhibitory postsynaptic currents
(mIPSCs) at cerebellar synapses between basket
cells and purkinje cells [83–85].
NMDARs play an important role in mediating
plasticity at excitatory synapses. Interestingly,
NMDARs are also critical to the plasticity of
GABAergic synapses (Fig. 1, Mechanism C).
GABAergic synapses can undergo inhibitory long‐
term potentiation (iLTP) or inhibitory long‐term
depression (iLTD), depending on the expression
and function of GABAA receptors or the GABA

Fig. 1

Proposed mechanisms of how NMDARs promote inhibition.

Mechanism A: NMDARs at glutamatergic synapse on interneuron
promote interneuron excitability. Mechanism B: NMDARs at
presynaptic terminal of GABAergic synapse promote development/
function of GABAergic synapse. Mechanism C: NMDARs on
excitatory neurons promote development of GABAergic synapse or
inhibitory long‐term potentiation. Mechanism D: Synaptic NMDARs
suppress excitatory synaptic transmission. Mechanism E: Ambient
glutamate‐activated extrasynaptic GluN2B‐containing NMDARs
suppress excitatory synaptic transmission. GABARA—GABAA receptor.

release from presynaptic terminal[86]. iLTP or
iLTD that relies on postsynaptic NMDARs has
been reported in many brain regions, such as
hippocampus [87], visual cortex and ventral teg‐
ment [88]. In visual cortex, presynaptic NMDARs
have been shown to contribute to iLTD in
developing optic tectum [79].
NMDARs also play a critical role in the
regulation of GABAergic synapse development
(Fig. 1, Mechanism C). Indeed, in the superior
colliculus activation of NMDARs has been shown
to stimulate GABAergic synapse development [89].
In addition, overexpression of a constitutively
active NMDAR subunit increases GABAergic
transmission in developing hippocampal neurons,
indicating a cell‐autonomous role of NMDARs in
promoting development of GABAergic synapses
[76]. On the other hand, genetic deletion of
NMDARs in different types of neurons leads to
a strong reduction of GABAergic transmission
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as well as inhibitory synapse density [76, 90],
suggesting a necessary role of NMDARs in
GABAergic synaptogenesis. Mechanistically, the
regulation of formation of GABAergic connec‐
tions by NMDARs in hippocampal neurons is
dependent on the C0 domain of the GluN1
subunit and requires Ca2+‐dependent calmodulin
binding to the C0 domain [76], showing that the
NMDAR acts a key signaling molecule for con‐
trolling inhibitory circuit wiring. Consistent with
the functional data, a fraction of NMDARs has
been found to co‐localize with GABAA receptors
at GABAergic synapses in developing brain
[91–93], providing anatomic evidence for a role
of NMDARs in GABAergic synapse development.
4.2 NMDARs promote excitability of GABAergic
neurons to provide inhibition
Another explanation to the question “Why
NMDAR blockade causes excitation?” is that, at
low doses, NMDAR antagonists preferentially act
on NMDARs on interneurons instead of those on
excitatory neurons (Fig. 1, Mechanism A), there‐
fore reducing interneuron activity and leading
to a disinhibition effect on the overall network
activity. This proposal is supported by the obser‐
vation that MK‐801 treatment leads to reduced
activity of GABAergic interneurons and sub‐
sequent increased activity of excitatory principal
neurons in rodent prefrontal cortex [73, 94].
It has also been reported that hippocampal
GABAergic interneurons are more sensitive to
NMDAR antagonists than excitatory neurons
[95, 96]. One possible mechanism underlying this
preferential effect of NMDAR antagonists on
interneurons is that interneurons have generally
higher frequency of firing compared with pyra‐
midal neurons, which causes a higher NMDAR
baseline activity through the depolarization‐
dependent removal of Mg2+ block. Therefore,
more “alert” NMDARs may be more sensitive to
antagonist blockade [97–99].
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In addition, NMDARs ablation in interneurons
has a comparable effect with NMDAR antag‐
onists. Conditional knockout of GluN1 in inter‐
neurons not only leads to cortical disinhibition
but also the schizophrenia‐like behaviors, which
display novelty‐induced hyperlocomotion,
deficits in nesting and short‐term social memory
[56, 100, 101]. These data also support the hypo‐
thesis that NMDAR loss‐of‐function in inter‐
neurons is important for NMDAR antagonist‐
induced cortical excitation and psychosis‐like
behaviors in rodents [102–105].
4.3

Basal NMDAR activity suppresses excita‐
tory synaptic transmission

NMDARs are known to cause depolarization and
contribute to excitatory synaptic transmission.
However, there is also evidence suggesting that
basal NMDAR activity suppresses excitatory
transmission [75] (Fig. 1, Mechanism D). In this
case, NMDAR blockade leads to attenuation of
suppression on excitatory synaptic transmission,
therefore promoting excitation and global neuro‐
nal activity.
In dissociated neuronal cultures, chronic (>12
hours) blockade of action potentials (APs) by
tetrodotoxin (TTX) potentiates excitatory synaptic
transmission by increasing membrane AMPAR
insertion. This is called homeostatic scaling [106].
Interestingly, NMDAR selective antagonist AP5
increases mEPSC amplitude quickly (after one
hour) in the presence of TTX. In addition, AP5
alone can also increase mEPSC amplitude after
3 hours treatment in the absence of TTX [75].
Increased miniature excitatory postsynaptic current
(mEPSC) amplitude is found to be consistent with
increased surface AMPAR insertion; and this
increase depends on local protein synthesis [75].
Taking all these data into consideration, it is logical
to propose that basal NMDAR activity suppresses
excitatory transmission in principal neurons.
In addition, other studies have also found
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that blockade of NMDARs rapidly potentiates
AMPAR‐mediated synaptic transmission [107,
108]. In acute hippocampal slices, 30 minutes
incubation of another NMDAR antagonist
ketamine (20 μM) is sufficient to enhance AMPAR‐
mediated evoked field excitatory postsynaptic
potential (fEPSPs), which sustains even after
ketamine wash off [108]. The potentiation is not
linked to increased presynaptic release probability
because of the unaltered paired‐pulse facilitation.
A different NMDAR antagonist MK‐801 has
similar effect as ketamine, supporting that blo‐
ckade of NMDAR is the underlying mechanism
of the ketamine‐induced synaptic potentiation
[108]. NMDAR blockade‐mediated synaptic po‐
tentiation requires the deactivation of eukaryotic
elongation factor 2 (eEF2) kinase (also called
CaMKIII), which triggers protein synthesis of
brain‐derived neurotrophic factor (BDNF) and
increase of surface AMPAR insertion [107, 108].
These suggest that basal NMDAR activity indeed
suppresses AMPAR‐mediated synaptic transmis‐
sion, and alleviation of which is sufficient to boost
synaptic transmission in a fast and sustainable
manner.
Genetic studies have also indicated that
NMDARs suppress functional maturation of
AMPAR‐mediated synaptic transmission. In
pyramidal neurons in hippocampus and cerebral
cortex, genetic deletion of NMDARs causes a
strong increase of AMPA EPSCs [109–113].
Similarly, knockout of the NMDAR GluN1 subunit
in midbrain dopaminergic neurons significantly
increases AMPAR‐mediated transmission [114,
115]. A recent study on hippocampal neurog‐
liaform cells has also demonstrated that NMDARs
inhibit excitatory synaptic transmission [116].
Together, these studies show that NMDARs
suppress the maturation of AMPAR‐mediated
synaptic transmission and maintain the silent
status of developing glutamatergic synapses [110].

5

NMDAR dysfunction and diseases

Abnormal NMDAR activity underlies many brain
disorders including psychosis, mood disorder,
epilepsy and neurodegenerative diseases, etc.
[4, 117, 118]. This part of the review will discuss
the role of NMDAR in schizophrenia, depression
and epilepsy. These three diseases are chosen
because both NMDAR dysfunction and ab‐
normalities in inhibition have been strongly
implicated in their etiology.
5.1

NMDAR, schizophrenia, and anti‐NMDAR
encephalitis

Schizophrenia is a devastating mental disorder
characterized by abnormal social behavior and
failure to understand reality. It affects about
1% of the world’s population [119]. Its clinical
symptoms are summarized into three major
categories: positive symptoms, negative symp‐
toms and cognitive deficits. Positive symptoms
include delusions, hallucinations, disordered
thoughts, and speech. Negative symptoms are
deficits of normal emotional response, including
lack of motivation, inability to experience pleasure
and poverty of speech. Cognitive deficits are also
recognized as a core feature of schizophrenia,
including dysfunction of work memory, long‐
term memory, attention, learning, etc. [120, 121].
Studies of schizophrenia pathology have
mainly been focused on dopamine hyperfunction
theory. This is supported by the finding that
the affinity of dopamine D2 receptor antagonist
correlates with their anti‐psychotic potency [122,
123]. However, this hyperdopaminergic hypo‐
thesis can only be best used to explain positive
symptoms of schizophrenia. Although the most
common antipsychotic drugs nowadays are D2
dopamine receptor antagonists, they are only
effective in treating positive symptoms, but not
negative symptoms or cognitive deficits [124].
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Therefore, it has been a hot topic to search for
other hypothesis that could explain all symptoms
of schizophrenia.
NMDAR antagonists can induce a psychotic
state that resembles all three clusters of schizo‐
phrenic symptoms in healthy people and also
may exacerbate the symptoms in schizophrenia
patients [125, 126]. Reduced NMDAR activity
caused by its antagonists results in schizophrenia‐
like behaviors, which suggests that hypofunction
of NMDARs might be one of the causes of schizo‐
phrenia, leading to the proposal of the NMDAR
hypofunction hypothesis for schizophrenia
[127, 128]. As NMDARs are expressed in both
excitatory glutamatergic and inhibitory GABAergic
neurons, it remains largely unclear whether the
NMDAR hypofunction in excitatory neurons,
inhibitory neurons, or both types of neurons cause
schizophrenia.
Hypofunction of inhibitory neurotransmission
has been implicated in schizophrenia pathology.
Expression of key GABA signaling components is
reduced in post‐mortem brain of schizophrenia
patients including PV and GAD67 [56, 129–131].
Deletion of the GluN1 subunit in PV inter‐
neurons in mouse mimics some key behavioral
features of schizophrenia [56, 100], and these
mutant mice are more susceptible to MK‐801
induced schizophrenia‐like deficits [101]. This
supports the idea that NMDAR hypofunction in
PV interneurons contributes to schizophrenia.
Another evidence that supports NMDARs
hypofunction hypothesis for schizophrenia comes
from patients with anti‐NMDARs encephalitis.
Anti‐NMDAR encephalitis is an autoimmune
disorder featured with psychosis. This disease is
caused by auto‐antibodies targeting NMDARs,
which could pass through blood‐brain barrier
(BBB) and lead to removal of NMDARs from
synapses [132, 133]. Anti‐NMDARs encephalitis
has two major triggers, virus and tumors [134].
About 20% of patients infected with herpes
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simplex encephalitis (HSE) develop antibodies
against NMDAR [135, 136]. Approximately 50%
of young women with ovarian teratoma develop
anti‐NMDAR encephalitis. In addition, anti‐
NMDARs encephalitis patients usually benefit
from removal of NMDARs as antigens in
peripheral [132, 133]. This line of evidence also
suggests that NMDAR loss‐of‐function con‐
tributes to psychosis and strongly supports the
NMDA hypofunction hypothesis.
There is also human genetic evidence sup‐
porting NMDAR hypofunction hypothesis [137].
A recent genome‐wide association study (GWAS)
has linked NMDAR gene variances to risk in
schizophrenia. Exome sequencing has identified
de novo mutations of GluN2A and GluN2B in schi‐
zophrenia patients [138–140]. These schizophrenia‐
related mutations tend to be located at amino‐
and carboxyl‐termini [138, 139]. The functional
impacts of these variances, although remain
mostly unclear, will be critical for dissecting the
role of NMDARs in schizophrenia.
5.2

NMDAR and depression

Depression is a widespread mental disorder,
affecting more than 300 million people worldwide
(WHO). It is also the major cause of suicide in
adults. The most popular antidepressants are
serotonin (5‐HT) or norepinephrine (NE) reuptake
inhibitors [141–143]. Although these drugs have
benefited many, some obvious disadvantages
remain. First, the antidepressant effects can only
be observed after a few weeks of treatment
[144, 145]. This suggests that 5‐HT and NE system
are unlikely the direct cause of depression.
Second, about 30% patients are resistant to these
drugs for reasons unknown [146, 147]. Third,
selective serotonin reuptake inhibitors [148]
antidepressants may increase the risk of suicide
[148, 149]. These caveats make current antide‐
pressants unsatisfying.
Recent clinical studies have shown that a
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low sub‐anesthetic dose of NMDAR antagonist
ketamine can generate quick and sustainable
anti‐depressant effects on treatment‐resistant
depression patients [150–152]. In fact, it was first
reported back in 1990 that NMDAR antagonists
including competitive AP‐7 and non‐competitive
MK‐801 exhibited antidepressant actions in mice
[153]. Scientists then proposed that direct NMDAR
inhibition might lead to rapid anti‐depression
actions [153]. This breakthrough suggests a new
mechanism of action for fast antidepressants,
and indicates that the glutamatergic system
malfunction may underlie depression. However,
higher dose ketamine is psychogenic and could
be abused for entertainment usage causing severe
side effects [154]. Therefore, it would be extremely
beneficial to understand the mechanism of
ketamine antidepressant effect and therefore to
instruct development of better antidepressant
with fast action and less side effects.
Ketamine is a non‐selective NMDAR anta‐
gonist, but whether its rapid antidepressant effect
depends on NMDARs remains controversial.
Zanos and coworkers [155] have indicated that a
ketamine metabolite (2R,6R)‐HNK (hydroxynor‐
ketamine) is essential to produce antidepressant
effect in mice by increasing AMPAR‐mediated
excitatory post‐synaptic potentials [156] in CA1
region, independent to its actions on NMDARs.
However, Suzuki et al. [157] has reported that
slightly higher concentration of (2R,6R)‐HNK
can significantly impair NMDAR function at rest
in hippocampal slices and deactivates eEF2K,
eliciting AMPAR‐dependent synaptic potentiation
to produce the anti‐depression effect. Meanwhile,
NMDAR‐dependent lateral habenula (LHb) burst
firing increases significantly in brain slice of
depressed rats, and ketamine inhibits bursting
in LHb to rapidly relieve depressed behaviors
in animal models in an NMDAR‐dependent
manner [158].
NMDARs are mainly known to mediate

excitatory synaptic transmission. However
ketamine at sub‐anesthetic doses significantly
increases extracellular level of glutamate in the
PFC in rats [94, 159], and can increase focal pre‐
frontal activity in healthy volunteers [94, 159].
These findings are rather surprising, because
one would expect that blockers of excitatory
transmission should decrease excitability. These
new evidences indicate that low dose ketamine
may preferentially suppress NMDARs on in‐
hibitory neurons to reduce principal neurons
inhibition from inhibitory neurons and indirectly
enhance overall neuronal activity to produce
antidepressant effects [94, 99]. However, other
studies have proposed that GABA receptor
hypofunction may lead to depressive disorders,
and enhancing GABAergic neurotransmission can
induce antidepressant‐like behaviors in rodents
[160, 161]. Therefore, the NMDAR dysfunction
hypothesis for depression requires further inve‐
stigations [162].
Different subunits of NMDARs have different
physiological and pathological functions. Which
NMDAR subtype(s) plays the key role in the
ketamine‐evoked antidepressant actions is an
interesting question. Hypermethylation of the
GRIN2A gene has been observed by epigenome‐
wide methylation analysis in human brain
specimens [163]. Decreased GluN2A expression
level in the prefrontal cortex, but increased
in the lateral amygdala of majority depressed
patients have been reported [164]. In animal
models, the homozygous knock‐in mice with a
Tyr‐1325‐Phe mutation in GluN2A to prevent its
phosphorylation/activation show antidepressant‐
like behaviors [165]. GluN2A KO mice also have
anxiolytic and antidepressant‐like behaviors.
However, locomotion of GluN2A KO mice is also
enhanced significantly. These observations com‐
plicate the interpretation of the role of NMDARs
in the regulation of anxiolytic and antidepressant‐
like behaviors [166]. The administration of
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selective GluN2A antagonist NVP‐AAM077 can
elevate the release of glutamate and 5‐HT, and
rescue depressant‐like activity in the forced‐swim
test [167]. These results support that GluN2A
plays an important role in the regulation and
treatment of depression. However, poor subtype
selectivity of NVP‐AAM077 makes it difficult to
rule out the potential involvement of GluN2B.
GluN2B can also contribute to ketamine‐
induced fast antidepressant effect. GluN2B‐
containing NMDARs are activated under non‐
stimulated conditions by ambient glutamate and
suppress excitatory transmission [168] (Fig. 1,
Mechanism E), and its inhibition would promote
protein synthesis and trigger antidepressant
actions in an mTOR (the mammalian target of
rapamycin)‐dependent manner. Importantly,
ketamine loses its efficacy in inducing anti‐
depressant‐like behaviors in mice with GluN2B
knockout in cortical principal neurons [168].
This suggests that GluN2B is necessary for
ketamine‐induced antidepressant effect. Mean‐
while, GluN2B antagonists can also rapidly
reverse the depression‐like behavioral deficits in
chronic unpredictable stress model. The rescue
result is long‐lasting, similar to the action of
ketamine [169]. In addition, fluoxetine, serotonin
reuptake inhibitor class of antidepressant, can
selectively inhibit GluN2B‐containing NMDARs
[170]. A recent clinical study has shown that
GluN2B selective antagonist CP‐101,606 can
significantly improve the patients’ mental status,
although with a much slower onset after
administration compared with ketamine [171].
These data support that GluN2B‐containing
NMDARs play a role in ketamine‐induced
antidepressant effect.
5.3

NMDAR and epilepsy

Epilepsy is a chronic and recurrent disorder
caused by abnormal electrical activity in the
brain. Epilepsy affects about 50 million people
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worldwide (WHO). The imbalance of inhibitory
and excitatory neurotransmission [172, 173] plays
a pivotal role in the pathogenesis of epilepsy.
Abnormal GABAergic function is believed to be
the key factor underlying epilepsy. Patients with
temporal lobe epilepsy have a region‐specific
decrease of GABAA receptors [174], reduced
hippocampal somatostatin and neuropeptide Y
interneurons [175] and altered excitatory and
inhibitory neurotransmission [176]. In animal
models, GABA‐immunoreactive cell density and
the number of GABA‐positive terminals are
reduced during motor focal epilepsy in rats.
Grafting of GABAergic progenitors decreases
seizure activity and abnormal behaviors in mice
[177]. Current GABA‐based anti‐epileptic drugs
work well for many epilepsy patients. However,
a significant portion of epilepsy patients are
resistant to these treatments [178], suggesting
that alternative mechanisms could exist in these
treatment‐resistant epilepsy patients.
Recently, NMDARs have drawn attention in
the pathophysiology of epilepsy. The evidence
comes from human genetic studies. Particularly,
GRIN2A missense mutations cause epileptic
aphasia and idiopathic focal epilepsy [117, 118,
179]. In addition, GluN2 mRNA increases in the
hippocampus of temporal lobe epilepsy patients
[180]. Blockade of GluN2C overexpression can
rescue epileptogenesis in a tuberous sclerosis
murine model [181]. These strongly support a
critical role of NMDAR in these two forms of
epilepsy and raise the possibility of a potential
role of NMDAR in epilepsy in general.
The underlying mechanism however remains
debatable. A key question is whether it is gain‐
of‐function or loss‐of‐function of NMDARs that
causes the disease. Interestingly, similar disease
symptoms can be triggered by both increased
and decreased NMDAR function. The missense
mutations in GRIN2A, such as A243V [118],
P552R [182], N615K [183], and L812M [184],
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enhance NMDAR function and cause neuronal
hyper‐excitation. However, other GluN2A variants
I184S and R518H are rather loss‐of‐function
mutants by reducing surface expression, current
amplitude and opening time, while also increasing
deactivation time [185]. Mutations P79R, C231Y,
G483R and M705V also reduce the response to
the co‐agonists [186]. It is unclear why both gain‐
and loss‐of‐function mutations of NMDARs could
cause epilepsy.

6

Pharmacological tools for NMDARs

NMDARs are widely distributed in the central
nervous system with many critical physiological
functions. Their hypo‐ or hyper‐activation are
associated with various brain diseases. Properly
designed pharmacological tools can help reveal
the NMDAR function and the associated
mechanisms of related diseases, and will be
potentially useful for clinical intervention. A few
mostly used or newly developed compounds are

discussed below. Structures of the mentioned
compounds are summarized in Fig. 2.
6.1 Agonists and co‐agonist transporter inhibitor
The activation of NMDA receptors requires not
only glutamate binding to GluN2 but also a
co‐agonist (glycine or D‐serine) binding to GluN1
[187, 188]. Agonists acting on the glutamate
binding site of NMDARs cause excitotoxicity,
therefore not useful to study NMDAR physiologi‐
cal function nor to treat patients [119, 189, 190].
Glycine and D‐serine are endogenous co‐agonists.
They can increase the affinity of glutamate bind‐
ing on GluN2 subunit [191] and might be useful to
treat diseases caused by NMDAR hypofunction,
such as schizophrenia [192]. D‐serine acts on
synaptic NMDARs, while glycine affects extrasy‐
naptic receptors[193]. Synaptic NMDARs play an
important role in long‐term potentiation, while
long‐term depression requires both synaptic and
extrasynaptic receptors [194].

Fig. 2 Structures of selected pharmacological tools targeting NMDAR. Row 1: agonists and co‐agonists; Row 2: antagonists; Row 3:
GluN2A and 2B subtype selective antagonists: Row 4: PAMs.
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Compared to agonists at the glutamate site,
glycine site co‐agonists are safer and do not usually
cause excitotoxicity. GLYX‐13, which acts at the
glycine site, shows fast antidepressant effects
and has no psychotomimetic effects [195, 196].
Glycine transporter (GlyT) is responsible to
reuptake extracellular glycine and can play a
critical role in regulating NMDAR signaling. GlyT
has two distinct subtypes, GlyT‐1 and GlyT‐2.
They are sodium‐dependent transporters and
can maintain local glycine concentrations at sub‐
saturation levels [197]. Studies on the GlyT‐1
knockout mice have shown that GlyT‐1 enhances
hippocampal NMDAR function and cognition
[198]. D‐serine and GlyT‐1 inhibitors can reverse
pre‐pulse inhibition [152] and latent inhibition
(LI) in schizophrenia animal models [199, 200].
D’Souza et al. [201] have demonstrated that
GlyT‐1 inhibitor has the antipsychotic potential.
However, GlyT‐1 inhibitor phase 3 clinical trials
on treating schizophrenia failed for lack of
efficacy [202].
6.2

Antagonists

Excitotoxicity‐induced neuronal death is mediated
by hyperactivation of iGluRs, particularly
NMDARs. It contributes to neuronal damage in
many neurological disorders including stroke,
traumatic brain injury, epilepsy, and neuro‐
degenerative diseases. NMDAR antagonists could
be useful in blocking excitotoxicity and neuronal
damage.
MK‐801, phencyclidine and ketamine are the
non‐competitive open channel blockers with
limited subunit selectivity [203]. Phencyclidine
was introduced as an anesthetic in 1957 but it
caused a high rate of acute psychosis reactions
and thus has never been approved for clinic
application [204]. To reduce the side‐effects, its
analogue ketamine was developed. Ketamine has
been used as the anesthetic for around 50 years
and low dose ketamine has rapid and sustained
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anti‐depressant effects in patients with treatment‐
resistant depression. MK‐801, phencyclidine and
ketamine have been used to induce animal models
of schizophrenia [205, 206]. Low affinity channel
blocker memantine has also been used to treat
moderate to severe Alzheimer’s disease [207].
2‐amino‐5‐phosphonovaleric acid (AP5) and
4‐(3‐phosphonopropyl) piperazine‐2‐carboxylic
acid (CPP) are common NMDAR competitive
antagonists. AP5 is racemic mixture of D‐ and
L‐isomers. The D‐isomer has higher potency
and efficacy [208]. AP5 has been used to study
NMDAR‐dependent physiology and pathology,
including epilepsy and memory impairments
in the mammals [209–211], but its penetration of
the blood‐brain barrier is poor [212]. The CPP,
an analogue of AP5, has the higher affinity for
[3H]D‐AP5 binding sites and is regarded as a
potential anticonvulsant [213]. However, its
clinical trials have failed [214, 215], as it can
impair memory in healthy human [216].
Different NMDAR subtypes have different,
sometime opposite physiological functions;
therefore subunit‐selective antagonists are also
developed. The first subunit‐selective NMDAR
antagonist is GluN2B‐selective antagonist ifen‐
prodil. Ifenprodil and its derivatives bind to
GluN2B amino terminal domain (ATD) [217, 218].
Ifenprodil has antiparkinsonian effects in the
MPTP‐Lesioned marmoset model [219]. CP101,606
and Ro25‐6981 also are GluN2B selective anta‐
gonists [220, 221]. Remarkably, GluN2B‐selective
antagonists do not induce side effects often
triggered by non‐selective NMDAR antagonists
in humans [222]. NVP‐AAM077 preferentially
acts on human GluN2A over GluN2B [223] and
has been used to study GluN2A [224, 225].
However, selectivity of NVP‐AAM077 is poor
on rodent GluN2A, which limits its application
in research [226]. GluN2A selective antagonists
for animal studies will be very useful to demon‐
strate the role of GluN2A containing NMDARs.
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Positive allosteric modulators

Another novel pharmacological tool to enhance
NMDAR activity is positive allosteric modulator
(PAM). This family of compounds act at distinct
sites as compared with agonists and do not
directly activate the receptors. Instead, they
enhance the receptor response to its agonists. In
theory, they have several distinct advantages
over agonists. PAMs usually display better
subtype selectivity, because they could act on
the sites that are less homologous compared
with generally more conserved agonist binding
pockets among different subtypes [227]. Also,
PAM does not directly activate NMDARs, there‐
fore may not cause excitotoxicity as agonists.
In addition, PAM’s potentiation depends on the
endogenous agonists, therefore enhances NMDAR
activity in a more physiologically relevant
manner. This could be particularly important
in maintaining endogenous neuronal activity
pattern.
Hackos and colleagues published a family of
orally available GluN2A selective PAMs using
cell based high throughput screening of random
chemical library and following lead optimi‐
zation [228–231]. These compounds potentiate
GluN2A‐containing NMDAR response to their
co‐agonists in both cellular and brain slice assays
with up to 20 nanomolar potency, with minimum
activity on GluN2B and GluN2C. They bind to
the GluN1‐GluN2A dimer interface of the extra‐
cellular ligand‐binding domains (LBD) and can
enhance NMDAR‐dependent synaptic plasticity
[228]. These compounds provide promising tools
to study GluN2A function.
Perszyk and colleagues reported a series of
subtype nonselective PAMs, which were con‐
verted from NAMs (negative allosteric modulator)
by subtle structural modifications. The effects
of these compounds depend on the subtype of
NMDARs and agonists concentration. Interest‐
ingly, these PAMs do not act at extracellular ATD

of the receptor, suggesting multiple allosteric
modification sites exist on NMDARs [232].
Some derivatives of carboxylated naphthalene
and phenanthrene can also modulate NMDAR
activity [233]. For example, UBP710 preferentially
potentiates GluN2A and GluN2B. It also acts
on GluN2C and GluN2D, but with a weaker
efficacy at lower doses and leads to 2C and 2D
inhibition at a higher dose. UBP608 inhibits
all GluN2 subtypes. Whereas, UBP512 action is
dependent on its dose. It potentiates GluN2A
and inhibits GluN2C and 2D at high doses, but
weakly inhibits GluN2A and 2B at lower doses.
ATD is unnecessary for the action of all these
compounds. In addition, S2 domain is important
for UBP512 and UBP710, and S1 domain is vital
for UBP608‐induced inhibition.
Meanwhile, (3‐chlorophenyl)(6,7‐dimethoxy‐
1‐((4‐methoxyphenoxy)methyl)‐3, 4‐dihydroiso‐
quinolin‐2(1H)‐yl)methanone (CIQ) can enhance
activity of GluN2C/2D by increasing their channel
open probability without affecting the open state,
and its action requires Thr592 in the M1 region
and the linker between the ATD and LBD [234].
NMDAR dysfunction or loss‐of‐function may
be the cause underlying several brain diseases,
such as schizophrenia and epilepsy, etc. Phar‐
macological tools enhancing NMDAR activity will
be very useful to compensate the compromised
NMDAR activity in these diseases and provide
benefits as a novel treatment. However, this
kind of drugs had not been available for a
long time. As discussed above, NMDAR PAMs
represent a new hope to solve this issue, which
could serve as an unprecedented opportunity to
treat these brain diseases in the future. However,
most these compounds are still at their early stage
of development. Although a few families of
NMDAR PAMs have been developed to enhance
NMDAR endogenous activity without evoking
excitotoxicity, their behavioral benefits have
remained to be addressed.
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7

Summary

Why do NMDAR antagonists cause excitation
instead of inhibition in the brain under certain
conditions? This represents one of the most
critical questions concerning NMDAR function.
Its answer would be essential to address etiology
of many related brain diseases, including psy‐
chosis, depression and certain forms of epilepsy.
Our review summarizes recent explanations for
this question. However, limited by available tools,
the answers remain controversial and largely
unclear. New emerging research tools, such as
novel subtype selective pharmacological reagents
(particularly gain of function tools like PAMs)
together with new genetic models would be very
useful to clarify this important question in the
near future.
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